Crucell signs non-exclusive antibody technology deal with Centocor
This article was originally published in Scrip
Executive Summary
Crucellhas signed a non-exclusive research and commercialisation agreement withCentocorfor the production of monoclonal antibodies using Crucell's STAR recombinant human antibody and protein production technology. The deal follows a similar agreement signed in May last year between Crucell and Dutch biopharmaceutical company Bioceros.